Cytosorbents (CTSO) Assets Average (2011 - 2026)

Cytosorbents' Assets Average history runs 15 years deep, the most recent figure standing at $42.4 million for Q1 2026.

• Quarterly Assets Average fell 13.66% year-over-year to $42.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.4 million (down 13.66% YoY) and the FY2025 annual result came in at $45.8 million, down 8.75% from the prior year.
• Assets Average was $42.4 million for Q1 2026 at Cytosorbents, down from $45.0 million in the prior quarter.
• Across five years, Assets Average topped out at $86.4 million in Q1 2022 and bottomed at $42.4 million in Q1 2026.
• A 5-year average of $55.3 million and a median of $50.2 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average sank 32.01% — and 2024, when it advanced 1.21%.
• Cytosorbents' Assets Average stood at $62.8 million in 2022, then retreated by 19.9% to $50.3 million in 2023, then declined by 5.33% to $47.6 million in 2024, then fell by 5.51% to $45.0 million in 2025, then retreated by 5.77% to $42.4 million in 2026.
• Business Quant data shows CTSO's Assets Average at $42.4 million in Q1 2026, $45.0 million in Q4 2025, and $46.9 million in Q3 2025.